Discovering TASOR: A Potential Drug Target and Biomarker (G23272)

Target Name: TASOR

NCBI ID: G23272

TASOR

Discovering TASOR: A Potential Drug Target and Biomarker

TASOR (Protein TASOR) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. TASOR is a protein that is expressed in various tissues throughout the body and is involved in the development and maintenance of blood vessels, as well as the regulation of cell growth and differentiation.

Recent studies have shown that TASOR plays a critical role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of TASOR are associated with an increased risk of cancer development and that inhibiting TASOR can lead to therapeutic benefits in cancer treatment.

In addition to its potential as a drug target, TASOR has also been identified as a potential biomarker for various diseases. For example, studies have shown that TASOR levels can be used as a diagnostic marker for cancer, as well as for other diseases such as cardiovascular disease and neurodegenerative disorders.

The discovery and identification of TASOR as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. If TASOR is found to be a valid drug target, it could lead to the development of new treatments that specifically target TASOR and have minimal unintended effects on other tissues. Additionally, if TASOR is found to be a valid biomarker, it could be used to diagnose and monitor the progression of various diseases.

While more research is needed to fully understand the role of TASOR in disease, its potential as a drug target and biomarker is an exciting area of study that has the potential to lead to new and effective treatments for a variety of diseases.

Protein Name: Transcription Activation Suppressor

Functions: Component of the HUSH complex, a multiprotein complex that mediates epigenetic repression (PubMed:26022416, PubMed:28581500). The HUSH complex is recruited to genomic loci rich in H3K9me3 and is required to maintain transcriptional silencing by promoting recruitment of SETDB1, a histone methyltransferase that mediates further deposition of H3K9me3, as well as MORC2 (PubMed:26022416, PubMed:28581500). Also represses L1 retrotransposons in collaboration with MORC2 and, probably, SETDB1, the silencing is dependent of repressive epigenetic modifications, such as H3K9me3 mark. Silencing events often occur within introns of transcriptionally active genes, and lead to the down-regulation of host gene expression (PubMed:29211708). The HUSH complex is also involved in the silencing of unintegrated retroviral DNA by being recruited by ZNF638: some part of the retroviral DNA formed immediately after infection remains unintegrated in the host genome and is transcriptionally repressed (PubMed:30487602). Plays a crucial role in early embryonic development (By similarity). Involved in the organization of spindle poles and spindle apparatus assembly during zygotic division (By similarity). Plays an important role in maintaining epiblast fitness or potency (By similarity)

The "TASOR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TASOR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets